Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is an aggressive type of cancer characterized by higher metastatic and reoccurrence rates, where approximately one-third of TNBC patients suffer from the metastasis in the brain. At the same time, TNBC shows good responses to chemotherapy, a feature that fuels the search for novel compounds with therapeutic potential in this area. Recently, we have identified novel urea-based compounds with cytotoxicity against selected cell lines and with the ability to cross the blood-brain barrier in vivo. We have synthesized and analyzed a library of more than 40 compounds to elucidate the key features responsible for the observed activity. We have also identified FGFR1 as a molecular target that is affected by the presence of these compounds, confirming our data using in silico model. Overall, we envision that these compounds can be further developed for the potential treatment of metastatic breast cancer. Image 1 • TNBC is a highly metastatic type of breast cancer with poor prognosis. • We have identified novel urea-based compounds with the activity against TNBC and ability to cross the BBB in vivo. • We identified potential off-target activity at DAT and structural requirements associated with this activity. • Our compounds induce apoptosis and modulate FGFR1 expression in MDA-MB-231 triple-negative breast cancer cell lines. [ABSTRACT FROM AUTHOR]